← FDA DRUG APPROVALS

FDA ANDA · ANDA076553

MEDROXYPROGESTERONE ACETATE

Sponsor: HONG KONG

APPLICATION
ANDA076553
TYPE
ANDA
ORIGINAL APPROVAL
2004-07-28
LATEST ACTION
2021-12-08
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

MEDROXYPROGESTERONE ACETATEPrescription
MEDROXYPROGESTERONE ACETATE 150MG/ML · INJECTABLE · INJECTION

Approval history

2021-12-08Labeling · Supplement 30 · standardAP
2021-12-08Labeling · Supplement 22 · standardAP
2021-12-08Labeling · Supplement 31 · standardAP
2021-12-08Labeling · Supplement 23 · standardAP
2011-11-30Labeling · Supplement 15AP
2005-03-04Labeling · Supplement 2AP
2004-07-28OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →